Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage. In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection...
Date First Received: May 30, 2008
Last Updated: June 3, 2008
Verified by: Illinois Retina Associates, May 2008
Clinical Trial Phase: Phase 4 | Start Date: July 2008
Overall Status: Not yet recruiting
Estimated Enrollment: 40
Brief Summary
Official Title: “To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection”
Condition Keyword(s):
Intervention(s):
Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.
In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Study Primary Completion Date: June 2009
Intervention(s) in this Clinical Trial
- Drug: Vigamox
- eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: Arm 1
- Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
- Active Comparator: Arm 2
- Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
Outcome Measures for this Clinical Trial
Primary Measures
- Timed study
- Time Frame: 1 year
Safety Issue?: No
- Time Frame: 1 year
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patient who need intravitreal injections patients who are willing to participate in the study
Exclusion Criteria:
- Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 21 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Illinois Retina Associates
Overall Clinical Trial Officials and Contacts
Kourous A Rezaei, MD Principal Investigator Illinois Retina Associates SC
Overall Contact: Kourous A Rezaei, MD 708-596-8710 karezaei@yahoo.com
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00690313
Study ID Number: Vig508
ClinicalTrials.gov Identifier: NCT00690313
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
